1
|
Garriga-Baraut T, Labrador-Horrillo M, Tena M, Linares CD, Esteso-Hontoria O, Pedemonte C, Basagaña-Torrento M, Miquel S, Padró-Casas C, Campa-Falcon N, Ferré-Ybarz L, Gázquez-Garcia V, Muñoz-Cano R, Viñas M, Farrarons L, Baltasar-Dragó M, Cortés N, Asensio O, Bartra J, Belmonte J, Bobolea I, Raga E, Moncín MSM. A real-life ImmunoCAT study: impact of molecular diagnosis through ImmunoCAP TM ISAC 112 on immunotherapy prescription in pollen-polysensitized patients in Catalonia, Spain. Allergol Immunopathol (Madr) 2024; 52:21-29. [PMID: 38970261 DOI: 10.15586/aei.v52i4.1077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 04/05/2024] [Indexed: 07/08/2024]
Abstract
BACKGROUND Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients. OBJECTIVE To assess the impact of molecular diagnosis through the ImmunoCAPTM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species. METHODS A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient's clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components. RESULTS A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray. CONCLUSIONS Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.
Collapse
Affiliation(s)
- Teresa Garriga-Baraut
- Pediatric Allergy Unit, Pediatric Department, Vall d'Hebron University Hospital, Barcelona, Spain;
| | - Moises Labrador-Horrillo
- Pediatric Allergy Unit, Pediatric Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Mercé Tena
- Thermo Fisher Scientific, Barcelona, Spain
| | | | | | - Carlos Pedemonte
- Pediatric Allergy Department, Hospital de Nens de Barcelona, Barcelona, Spain
| | | | - Sira Miquel
- Allergy Department, Germans Trias i Pujol Hospital, Badalona, Spain
| | | | - Núria Campa-Falcon
- Pediatric Allergy Unit, Pediatric Medicine Service, Parc Taulí Hospital, Sabadell, Spain
| | | | | | | | - Marta Viñas
- Allergy Department, Terrassa Hospital, Terrrassa, Spain
| | - Lidia Farrarons
- Allergy Department, Fundació Althaia Hospital, Manresa, Spain
| | | | - Núria Cortés
- Pediatric Allergy Department, Mútua de Terrassa Hospital, Terrassa, Spain
| | - Oscar Asensio
- Pediatric Allergy Unit, Pediatric Medicine Service, Parc Taulí Hospital, Sabadell, Spain
| | - Joan Bartra
- Allergy Department, Clínic Hospital, Barcelona, Spain
| | | | - Irina Bobolea
- Allergy Department, Clínic Hospital, Barcelona, Spain
| | - Esperanza Raga
- Allergy Department, Centro Médico Téknon, Barcelona, Spain
| | | |
Collapse
|
2
|
Cacheiro-Llaguno C, Mösges R, Calzada D, González-de la Fuente S, Quintero E, Carnés J. Polysensitisation is associated with more severe symptoms: The reality of patients with allergy. Clin Exp Allergy 2024. [PMID: 38676405 DOI: 10.1111/cea.14486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 04/03/2024] [Accepted: 04/12/2024] [Indexed: 04/28/2024]
Abstract
BACKGROUND Studying the sensitisation profiles of patients with allergies allows for a deeper understanding of the disease which may facilitate the selection of the best-personalised allergen immunotherapy. This observational, cross-sectional, multicentre study aimed to demonstrate the heterogeneity of the German population with allergies by analysing specific immunoglobulin E (sIgE) patterns towards aeroallergens and exploring the relationship between sensitisation and clinical symptoms. METHODS In total, 500 patients with allergies from different regions of Germany were recruited based on their case histories, clinical allergic symptoms and skin prick test data for aeroallergens. Serum samples were analysed using ImmunoCAP assays to determine sIgE levels for 33 allergenic sources and 43 molecular allergens. RESULTS Most patients (81%) were polysensitised. Betula verrucosa pollen was the most common cause of sensitisation (59%), followed by Phleum pratense (58%) and Dermatophagoides pteronyssinus (44%). The highest prevalence rates of molecular allergens were observed for Bet v 1 (84%) from birch pollen, Phl p 1 from grass pollen (82%), Der p 2 (69%) from mites and Fel d 1 (69%) from cat. Polysensitisation was significantly associated with the presence of asthma and the severity of rhinitis symptoms. CONCLUSIONS Our findings show a high rate of polysensitisation and emphasise the importance of molecular diagnosis for more precise and comprehensive insights into sensitisation patterns and their association with clinical symptoms. These data may help improve personalised diagnosis and immunotherapy adapted to the needs of individual patients in the region.
Collapse
Affiliation(s)
| | - Ralph Mösges
- IMSB, Faculty of Medicine, University of Cologne, Cologne, Germany
- ClinCompetence Cologne GmbH, Cologne, Germany
| | - David Calzada
- R&D Allergy and Immunology Unit, LETI Pharma, Madrid, Spain
| | | | - Eliana Quintero
- IMSB, Faculty of Medicine, University of Cologne, Cologne, Germany
- Praxis Dr. Kasche und Kollegen, Hamburg, Germany
| | | |
Collapse
|
3
|
González-Pérez R, Poza-Guedes P, Pineda F, Sánchez-Machín I. Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy. Curr Issues Mol Biol 2023; 45:9976-9984. [PMID: 38132469 PMCID: PMC10742397 DOI: 10.3390/cimb45120623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/10/2023] [Accepted: 12/11/2023] [Indexed: 12/23/2023] Open
Abstract
Allergen immunotherapy (AIT) with aeroallergens is the only disease-modifying treatment for patients with different allergic conditions. Despite the effectiveness of AIT having been proven in both randomized controlled trials and real-world studies, it remains underused in less than 10% of subjects with allergic rhinitis (AR) and/or asthma (A). We aimed to determine the current eligibility for house dust mite (HDM) AIT by means of a precision allergy molecular diagnosis (PAMD@) model in a selected cohort of youngsters with different allergic phenotypes according to the available evidence. A complex response to both HDM and storage mite allergens was depicted regardless of the subjects' basal atopic condition. No solely specific IgE-binding responses to Der p 1, Der p 2, and/or Der p 23 were found in the studied cohort. Despite the patients with A and atopic dermatitis showing significantly higher serum titers to six mite allergens than subjects with AR, no specific molecular profile was regarded as disease specific. Given the increasing complexity of specific IgE responses to the local prevailing aeroallergens, the identification and presence of such molecules are needed in commercially available AIT in the era of precision medicine.
Collapse
Affiliation(s)
- Ruperto González-Pérez
- Allergy Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain; (P.P.-G.); (I.S.-M.)
- Severe Asthma Unit, Hospital Universitario de Canarias, 38320 Tenerife, Spain
| | - Paloma Poza-Guedes
- Allergy Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain; (P.P.-G.); (I.S.-M.)
- Severe Asthma Unit, Hospital Universitario de Canarias, 38320 Tenerife, Spain
| | | | - Inmaculada Sánchez-Machín
- Allergy Department, Hospital Universitario de Canarias, 38320 Tenerife, Spain; (P.P.-G.); (I.S.-M.)
- Allergen Immunotherapy Unit, Hospital Universitario de Canarias, 38320 Tenerife, Spain
| |
Collapse
|
4
|
Abushal BA, Bormah A, Alghamdi M, Tubaigi YS, Alomari A, Khan SN, Alhafez NA, Aladni IS. Allergic Rhinitis: Tailoring Immunotherapy Through Innovative Diagnostics. Cureus 2023; 15:e51370. [PMID: 38292952 PMCID: PMC10825500 DOI: 10.7759/cureus.51370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/30/2023] [Indexed: 02/01/2024] Open
Abstract
Allergic rhinitis (AR) is a chronic ailment triggered by immunoglobulin E (IgE)-mediated reactions to allergens. Generally, AR is accompanied by asthma and conjunctivitis. The risk factors of AR include both inhalant and occupational allergens and genetic factors. Although AR is not a life-threatening condition, it poses a significant risk of morbidity and hampers work-related performance. Currently, the diagnosis of AR is based on clinical history and physical examination of the patients. Furthermore, several laboratory tests such as skin pricking test (SPT), nasal allergen challenge (NAC), and computed tomography (CT) are also recommended in some cases. Nasal cytology can aid in the differentiation of rhinitis because of allergy or infection. Apart from this, molecular diagnostic modalities such as basophil activation test (BAT) and Immune Solid-Phase Allergy Chip (ISAC) can also be employed for the confirmatory diagnosis of AR. Immunotherapy has demonstrated efficacy in the management of AR, with only mild side effects. With the advancement in the diagnostic realm of AR, personalized treatment approach has also gained significant popularity. Immunotherapy is gaining evidence on becoming a personalized treatment approach for the management of AR. This article provides a comprehensive overview, aiming to bridge the gap between evolving diagnostics and personalized therapeutic strategies for allergic rhinitis.
Collapse
Affiliation(s)
| | | | - Malak Alghamdi
- Department of Family Medicine, College of Medicine, Albaha University, Al Baha, SAU
| | - Yahay S Tubaigi
- Department of Medicine, Eradah Mental Health Complex, Jeddah, SAU
| | - Amal Alomari
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, SAU
| | - Safwan N Khan
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, SAU
| | | | - Ibrahim S Aladni
- Department of Ophthalmology, King Abdulaziz University Hospital, Jeddah, SAU
| |
Collapse
|